INSM Stock On Track For Best Day In Over 3 Months After Sanofi Buyout Talks
Sanofi is talking to advisers and studying a potential deal for Insmed, Bloomberg reported, citing unnamed people familiar with the matter.
Archived explainer. For the current picture see today's INSM page.
INSMED INC (INSM) is up +18.40% in the latest session. Our newswire has captured 15 stories on INSM across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Insmed (INSM) shares surged 18.40% to close at $141.84, driven by reports that Sanofi is exploring a potential acquisition of the biopharmaceutical company. The stock opened at $119.45 and reached an intraday high of $149.07 at 10:15 AM ET before settling near the upper end of the range. Trading volume reached 8.2 million shares, representing 2.9 times the three-month daily average.
Sanofi is currently consulting with advisers and evaluating a potential deal to acquire Insmed, according to sources familiar with the matter. This development marks a significant shift for the company, which had already been experiencing upward momentum. Prior to this news, the stock had gained 3.2% over the previous eight sessions, moving from $116.10 to $119.80. The acquisition speculation arrived alongside an update on the company’s ongoing clinical study, the INSPIRE AT longitudinal study, which provided an early signal for its pediatric rare-disease pipeline.
The market capitalization of Insmed stands at $26.7 billion, with the company currently unprofitable and reporting a trailing twelve-month earnings per share of negative $2.80. Despite the lack of profitability, revenue growth has been robust at 240.0% on a trailing twelve-month basis, though the net margin remains negative at 39.9%. The stock’s beta is 0.81, indicating lower volatility relative to the broader market. The 52-week range spans from $90.39 to $212.75, and the recent move contributed to 12 fresh 52-week highs recorded on November 19, 2026.
Insider activity shows one sale totaling $3.1 million in the last 90 days, with the most recent filing dated September 11, 2026. Director David R. Brennan sold shares on September 9, 2026. Congressional disclosures indicate Donald J. Trump bought between $15,001 and $50,000 on July 17, 2026, and sold between $1,001 and $15,000 on June 16, 2026. Retail sentiment has improved, with the seven-day average rising to 65 out of 100 from a 30-day average of 59.
Market participants will monitor further developments regarding the Sanofi acquisition talks and any official statements from either company. Additionally, the breadth of analyst coverage, which currently includes 15 stories from eight sources in the last 36 hours, suggests heightened scrutiny on the company’s valuation and strategic direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Sanofi is talking to advisers and studying a potential deal for Insmed, Bloomberg reported, citing unnamed people familiar with the matter.
Insmed ($INSM) announced an update on their ongoing clinical study. Study Overview: Insmed’s INSPIRE AT study, officially titled “INSPIRE AT: Longitudinal Study Com...
Insmed stock jumps following a report saying Sanofi is eyeing a takeover of the biopharma company.
Sanofi weighs takeover of US drugmaker Insmed, Bloomberg News reports
More on INSM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier INSM move explainers: 2026-11-20 · 2026-11-19 · 2026-10-30 · 2026-10-29 · 2026-10-06 · 2026-10-05 · 2026-08-07 · 2026-08-06